Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances

Entrada Therapeutics, Inc.

2025-FY EPS reported -$3.47 revenue$25,421,000

Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.
Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.
DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.
ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.
Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.